








Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Batt, SM, Burke, CE, Moorey, AR & Besra, GS 2020, 'Antibiotics and resistance: the two-sided coin of the
mycobacterial cell wall', The Cell Surface, vol. 6, 100044. https://doi.org/10.1016/j.tcsw.2020.100044
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 11. May. 2021
Contents lists available at ScienceDirect 
The Cell Surface 
journal homepage: www.journals.elsevier.com/the-cell-surface 
Antibiotics and resistance: the two-sided coin of the mycobacterial cell wall 
Sarah M. Batt, Christopher E. Burke, Alice R. Moorey, Gurdyal S. Besra⁎ 
Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK  







A B S T R A C T   
Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, is the global leading cause of mortality 
from an infectious agent. Part of this success relies on the unique cell wall, which consists of a thick waxy coat 
with tightly packed layers of complexed sugars, lipids and peptides. This coat provides a protective hydrophobic 
barrier to antibiotics and the host’s defences, while enabling the bacterium to spread efficiently through sputum 
to infect and survive within the macrophages of new hosts. However, part of this success comes at a cost, with 
many of the current first- and second-line drugs targeting the enzymes involved in cell wall biosynthesis. The flip 
side of this coin is that resistance to these drugs develops either in the target enzymes or the activation pathways 
of the drugs, paving the way for new resistant clinical strains. This review provides a synopsis of the structure 
and synthesis of the cell wall and the major current drugs and targets, along with any mechanisms of resistance.   
1. Introduction 
Mycobacterium tuberculosis (Mtb), the causative agent of tubercu-
losis, has a mortality rate of over 1.5 million a year (World Health 
Organisation, 2019). A crucial part of this pathogenicity is the ex-
tremely unusual cell wall of mycobacteria, and as such many of the 
current antibiotic regimes target essential enzymes involved in its 
synthesis. The first-line drug regimen is a combination of antibiotics, 
consisting of ethambutol, isoniazid, rifampicin and pyrazinamide 
(World Health Organization, 2017). Since these drugs have been used 
for more than 60 years, multi-drug resistant strains (MDR) have de-
veloped, with mutations in the target enzymes or drug activation 
pathways. Second-line drugs, which include capreomycin, ethionamide 
and streptomycin, are the next level of treatment for those with re-
sistant strains (World Health Organisation, 2011). However, ex-
tensively drug resistant strains (XDR), which are additionally resistant 
to second-line drugs, are also emerging (World Health Organisation, 
2011). This has resulted in a surge of research into mycobacteria, in the 
hopes of finding new effective drugs and targets. As many of the current 
drugs, and those under development, target the cell wall (see Fig. 1 for 
examples in red), an understanding of the complex biosynthesis path-
ways and mechanisms of drug inhibition and resistance, is a valuable 
part of this research. 
The cell envelope of mycobacteria (Fig. 1) is a waxy, hydrophobic 
coat, with a high percentage of lipids (40%) (Asselineau and Lederer, 
1950), imparting this pathogen with an effective barrier to antibiotics 
(Brennan and Nikaido, 1995; Minnikin, 1982) and the host’s immune 
system (Harding and Boom, 2010; Murry et al., 2009; Reed et al., 
2004), as well constituting key virulence factors (Fratti et al., 2003; 
Glickman et al., 2000; Maeda et al., 2003; Quigley et al., 2017; 
Schlesinger et al., 1994). Though classified as a Gram-positive, myco-
bacteria actually possess an outer membrane or “MOM” (mycobacterial 
outer membrane), which is not typical of Gram-negatives either. This 
MOM consists of an inner layer of mycolic acids (MAs) and an outer 
leaflet of free-lipids (Fig. 1) (Barksdale and Kim, 1977; Christensen 
et al., 1999; Minnikin, 1982; Zuber et al., 2008). The MA layer is 
covalently linked to the arabinogalactan (AG), a domain of heavily 
branched arabinose chains connected to a galactan trunk, which in turn 
is attached to the peptidoglycan, forming the mycolyl-arabinogalactan- 
peptidoglycan (mAGP) complex (Barry et al., 2007; Brennan and 
Nikaido, 1995; Crick et al., 2010; 2001). Also present are the lipogly-
cans, lipomannan (LM) and lipoarabinomannan (LAM), which are an-
chored within the inner membrane and project out into the periplasmic 
space, though there is some evidence to suggest that they also reside in 
the lipids of the MOM (Minnikin et al., 2015; Ortalo-Magne et al., 1996; 
Pitarque et al., 2008; Sani et al., 2010). The inner membrane of my-
cobacteria is also rather unconventional, containing a high proportion 
of phosphatidyl-myo-innositol mannosides (PIMs), which serve to im-
prove the membrane’s stability and barrier to drugs (Bansal-Mutalik 
and Nikaido, 2014). 
This review will discuss the structures and biosynthesis of the major 
components of the Mtb cell envelope, including the current drugs that 
target their synthesis and transport, and in turn the resistance me-
chanisms that have developed. Interesting drugs in the pipe-line and 
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new target enzymes will also be considered, along with the changing 
aspects of research into drug discovery. 
2. The cell wall core 
2.1. Peptidoglycan structure 
Peptidoglycan (PG) is common to all bacteria and provides crucial 
mechanical strength to the cell wall in order to resist internal cellular 
hydrostatic pressure and maintain shape, any disruption of which leads 
to bactericidal cell lysis (Vollmer et al., 2008). While for most bacteria, 
the peptidoglycan also provides a major anchoring point on the exterior 
of the cell for further modifications, uniquely in mycobacteria, it forms 
the base for the entire mycobacterial outer membrane complex, the 
mAGP (Brennan and Nikaido, 1995). Structurally, PG consists of long 
β(1 → 4)-linked glycan backbone chains of repeating N-acet-
ylglucosamine (GlcNAc) and N-acetylmuramic acid residues (MurNAc), 
cross-linked together via peptide side-chains of five amino acids, to 
form a mesh-like macromolecule (Fig. 2A) (Brennan and Nikaido, 
1995). Though a common A1γ subtype found in many bacteria in-
cluding Escherichia coli (E. coli) (Brennan and Nikaido, 1995; Schleifer 
and Kandler, 1972), mycobacterial PG has several modifications to the 
structural features. The muramic acid residues, for instance, are present 
as a mixture of both the typical MurNAc and a hydroxylated derivative, 
N-glycolylmuramic acid (MurGlyc), in mycobacteria (Mahapatra et al., 
2005). The reason for this has yet to be determined, however it is 
thought that the glycolyl derivative has the potential to form additional 
hydrogen bonds, thereby increasing the strength of the PG (Brennan 
and Nikaido, 1995). The sequence of the mycobacterial peptide linker is 
L-alanine (L-Ala), D-isoglutamate (D-isoGlu), meso-diaminopimelate (m- 
DAP), D-alanine (D-Ala) and D-Ala (Brennan and Nikaido, 1995); fur-
ther modifications of these amino acids include the amidation of the 
free carboxylic acids of D-isoGlu, m-DAP and the terminal D-Ala, though 
the significance of this is not known (Mahapatra et al., 2005). Another 
deviance from the usual PG structure is the cross-linking of the peptide 
chains, which consist mostly of 3 → 3 linkages between two central m- 
DAP residues in mycobacteria, with fewer of the 3 → 4 m-DAP to D-Ala 
linkages common to most prokaryotes (Kumar et al., 2012; Lavollay 
et al., 2008). Mycobacteria also have significantly more peptide cross- 
links (up to 70–80%) compared to other species, such as E. coli (50%), 
which provides additional mechanical strength to the mesh-like struc-
ture (Matsuhashi, 1966; Vollmer and Holtje, 2004). The PG is attached 
to the arabinogalactan (AG) via a unique linker unit in mycobacteria, α- 
L-rhamnopyranose-(1 → 3)-α-D-GlcNAc(1 → P), which forms the con-
nection through a phosphodiester bond to the 6-OH of the muramic 
residues in the glycan backbone (Fig. 3A) (McNeil et al., 1990). 
Fig. 1. The cell wall of Mycobacterium tu-
berculosis. The inner leaflet of the plasma 
membrane contains a high quantity of Ac1/ 
Ac2PIM2 (tri- and tetra-acylated phospha-
tidyl-myo-inositol-dimannoside), while the 
outer membrane has Ac1/Ac2PIM6 (tri- and 
tetra-acylated phosphatidyl-myo-inositol- 
hexamannoside), along with the more 
usual phospholipids, DPG (dipho-
sphatidylglycerol), PE (phosphatidyletha-
nolamine) and PI (phosphatidylinositol); 
the methyl groups of the unique tubercu-
lostearic acids of mycobacteria are depicted 
here (Minnikin et al., 2015). Also anchored 
into the plasma membrane are LM (lipo-
mannan) and LAM (lipoarabinomannan), 
which project out into the periplasm; the 
mannose sugars and mannan domains are 
coloured light blue and the branched ara-
binan is green. According to the ‘scaffold 
model’, the glycan back bone (purple) of the 
PG (peptidoglycan) forms a matrix of he-
lices orientated perpendicular to the plasma 
membrane (Dmitriev et al., 2000). These 
surround the AG (arabinogalactan) and 
LAM (lipoarabinomannan) and are con-
nected by the peptide cross-links (coloured 
circles: orange = L-alanine, yellow = D- 
isoglutamine, green = meso-diaminopime-
late and blue = D-alanine). The PG is con-
nected to the base of the Gal (galactan; or-
ange) via a unique rhamnose-N- 
acetylglucosamine linker. Three highly 
branched Ara (arabinan; green) domains 
project from the base of the Gal towards the 
MA layer (mycolic acids; dark blues and 
purples), which is covalently attached to 
most of the non-reducing ends of the Ara 
and forms the inner layer of the MOM 
(mycobacterial outer membrane). The PG, 
AG and MA make up the mycolylar-
abinogalactan-peptidoglycan complex (mAGP). The free lipids of the outer leaflet consist of PDIM (phthiocerol dimycocerosates); DAT, TAT, PAT and SGL (di-, tri- 
and penta-acyl trehalose and sulfated trehalose glycolipids) (Jankute et al., 2015; Minnikin et al., 2015). The diagram is roughly to scale using dimensions obtained 
from cryo-electron microscopy (Zuber et al., 2008). The main current and pipe-line drugs targeting the biosynthesis/transport pathways of the cell wall are shown in 
red. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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Earlier models of the 3D structure of PG within the cell envelope 
depicts the layers of the glycan backbone lying along the same plane as 
the plasma membrane (Ghuysen, 1968), orientated perpendicularly to 
the MAs. However, this model could theoretically result in gaps within 
the structure of the PG, and a recent ‘scaffold model’ instead positions 
the glycan back-bones as helices, perpendicular to the plasma mem-
brane (Fig. 2B) (Dmitriev et al., 2000). These helices are proposed to 
form a matrix with central spaces or ‘pores’ within each set of four 
peptide-linked helices, that could surround an AG moiety or other 
structure such as LAM (Dmitriev et al., 2000). This idea sustains bio-
chemical (Besra and Brennan, 1997), chemical (Besra et al., 1995) and 
EM data (Rastogi et al., 1991) and has since been further supported by 
Nuclear Magnetic Resonance data (Meroueh et al., 2006). 
2.2. Peptidoglycan biosynthesis 
PG biosynthesis (Fig. 2C) begins in the cytoplasm with GlmU 
(Rv1018c), an enzyme with two sequential functions in the synthesis of 
uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) (Zhang et al., 
2009). As an acetyltransferase, GlmU first transfers an acetyl group 
from acetyl-coenzyme A (acetyl-CoA) to glucosamine-1-phosphate, 
producing N-acetylglucosamine-1-phosphate (Zhang et al., 2009), 
which is further modified by GlmU’s uridyltransferase activity and UTP, 
into UDP-GlcNAc (Zhang et al., 2009). This is either incorporated into 
Lipid II as mentioned later, or converted into UDP-MurNAc, a process 
that is carried out by MurA (Rv1315) and MurB (Rv0482). MurA, a 
UDP-GlcNAc enolpyruvyl transferase, first transfers enolpyruvate, from 
phosphoenolpyruvate, to the UDP-GlcNAc, forming UDP-N-acet-
ylenolpyruvylglucosamine (De Smet et al., 1999). MurB (Rv0482) is a 
Fig. 2. Structural features of peptidoglycan and biosynthesis A) Chemical structure of peptidoglycan (see key for details). B) Diagram of the ‘scaffold model’ of 
peptidoglycan. The glycan (purple) of the peptidoglycan forms a matrix of helices orientated perpendicular to the plasma membrane, joined together by peptide 
cross-links and forming central pores to fit other structures, such as arabinogalactan (AG; orange and green helices) (Dmitriev et al., 2000). C) Biosynthesis of 
peptidoglycan. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Fig. 3. Structural features of arabinogalactan and biosynthesis A) Chemical structure of arabinogalactan. B) Biosynthesis of arabinogalactan and the rhamnose-N- 
acetylglucosamine linker unit. 
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UDP-N-acetylenolpyruvylglucosamine reductase that next reduces the 
enolpyruvate group, using the cofactor NADPH, to UDP-MurNAc 
(Eniyan et al., 2018). In mycobacteria, much of the UDP-MurNAc is 
hydroxylated to UDP-MurGlyc by NamH, a UDP-MurNAc hydroxylase 
(Mahapatra et al., 2005; Raymond et al., 2005). The penta-peptide side 
chain is added to the UDP-MurGlyc/NAc by the ATP-dependant Mur 
ligases: MurC, MurD and MurE (Rv2152c, Rv2155c and Rv2158c), 
which ligate L-Ala, D-isoGlu and m-DAP sequentially (Kurosu et al., 
2007; Munshi et al., 2013). The peptide sidechain is completed by MurF 
(Rv2157c) adding a D-Ala:D-Ala dipeptide subunit (Munshi et al., 
2013), which is synthesised by Ddl, a D-Ala-D-Ala ligase (Rv2981c) 
(Bruning et al., 2011). This muramyl-pentapeptide unit, known as the 
Park’s nucleotide (Chen et al., 2016), is then anchored into the inner 
membrane by MurX (Rv2156c) (a phospho-N-acetylmuramoyl-penta-
peptide transferase, also known as MraY), which conjugates a dec-
aprenyl phosphate (C50-P), producing Lipid I (Chen et al., 2016; Kurosu 
et al., 2007). The glycosyltransferase, MurG (Rv2153c), then converts 
Lipid I to Lipid II, transferring a UDP-GlcNAc to the muramic acid re-
sidue of Lipid I, with β(1 → 4) linkage (Lecreulx et al., 1991). 
Lipid II is next translocated across the inner membrane to the 
periplasm. The protein responsible for this was initially thought to be 
either MurJ (Rv3910) or the Shape, Elongation, Division, Sporulation 
(SEDS) protein, FtsW (Rv2154c) (Leclercq et al., 2017; Mohammadi 
et al., 2011; Ruiz, 2015; 2008; Sham et al., 2014). Recent evidence 
points to MurJ as the more likely flippase (Zheng et al., 2018) and to 
FtsW as a PG glycosyl transferase (Emami et al., 2017; Meeske et al., 
2016; Taguchi et al., 2019). Native mass spectroscopy has demon-
strated in vitro binding of the E. coli MurJ to Lipid II (Bolla et al., 2018) 
and the crystal structure of MurJ from Thermosipho africanus (MurJTA) 
has also provided evidence of MurJ’s role in Lipid II transport (PDB IDs: 
5T77, 6NC6, 6NC7, 6NC8 and 6NC9) (Kuk et al., 2019; 2017). MurJTA 
was shown to have a cytoplasmic entrance and a periplasm exit, as well 
as a cytoplasmic gate and a central cavity that crystallised in both in-
ward- and outward-open conformations, demonstrating how MurJ 
might flip Lipid II (Kuk et al., 2019; 2017). Electron density, hypothe-
sised to be Lipid II, was present in the portal and central cavity of the 
inward configuration of MurJTA; this portal is thought to regulate the 
entry of Lipid II into the central cavity of MurJ (Kuk et al., 2019). 
Once on the exterior face of the membrane, Lipid II is polymerised 
into a chain of PG by the mono-functional and bi-functional penicillin 
binding proteins (PBPs) (Sauvage et al., 2008). The bi-functional PBPs, 
PonA1 (Rv0050), PonA2 (Rv3682) and PonA3, have both a transgly-
cosylase domain for polymerising the glycan backbone, and a D,D- 
transpeptidase domain to form the 3 → 4 crosslinks between m-DAP 
and D-Ala of adjacent peptide side-chains, cleaving the terminal D-Ala 
from one side-chain (Kieser et al., 2015; Patru and Pavelka, 2010). In 
mycobacteria, however, 80% of the crosslinks are the non-classical 3 → 
3 linkage (Kumar et al., 2012; Lavollay et al., 2008). These cross-links 
are formed by the combined activities of the D,D-carboxypeptidases of 
the monofunctional PBPs, which remove the terminal D-Ala from one 
sidechain (Pandey et al., 2018), followed by the activity of the L,D- 
transpeptidases (Ldts), which cleaves the next D-Ala and forms a 3 → 3 
crosslink between two m-DAP residues of nearby sidechains 
(Laponogov et al., 2009). There are two Ldts encoded in the Mtb 
genome, termed LdtMt1 (LdtA; Rv0116c) and LdtMt2 (LdtB; Rv2518c) 
(Gupta et al., 2010), which are structurally unrelated to the PBPs and 
contain an active-site cysteine instead of serine (Biarrotte-Sorin et al., 
2006; Mainardi et al., 2005). 
2.3. Drugs targeting peptidoglycan synthesis and resistance mechanisms 
Due to the structural importance of PG, it is an attractive target for 
antimicrobials. Indeed, part of the mammalian innate immune system is 
the production of lysozyme, an enzyme that hydrolyses the β(1 → 4) 
links between GlcNAc and MurGlyc/NAc in the glycan backbone 
(Berger and Weiser, 1957; Chipman and Sharon, 1969); mycobacteria 
have a measure of resistance to lysozyme, which is conferred by the 
modification of MurNAc to MurGlyc (Raymond et al., 2005). The most 
well-known antibiotics that target the biosynthesis of PG are the β- 
lactams, analogues of D-Ala-D-Ala that bind irreversibly to the active 
site of the PBP’s transpeptidase domain (Kurz and Bonomo, 2012), 
preventing 3 → 4 peptide crosslinking. Whilst β-lactams are highly 
active against both Gram-positive and Gram-negative bacteria, in my-
cobacteria, most of the peptide crosslinking is 3 → 3 and constructed by 
the structurally distinct Ldts, which are not inhibited by most β-lactams 
(Kurz and Bonomo, 2012; Mainardi et al., 2005). Additionally, in many 
bacteria, resistance to β-lactams has developed in the form of β-lacta-
mases, which destroy the lactam ring. Mycobacteria are no exception to 
this and express the enzyme, BlaC (Rv2068c), a broad spectrum and 
highly active β-lactamase (Wang et al., 2006). These factors have meant 
that β-lactams were not considered as a treatment for mycobacteria for 
a long time. Recently though, a combinatorial regime has been devel-
oped for Mtb that utilises carbapenem, a β-lactam able to inhibit the 
Ldts and D,D-carboxypeptidases of mycobacteria (Cordillot et al., 2013; 
Dubée et al., 2012; Hugonnet et al., 2009; Kumar et al., 2012), with a β- 
lactamase inhibitor, clavulanic acid, which inhibits BlaC (Hugonnet 
et al., 2009; Hugonnet and Blanchard, 2007; Tremblay et al., 2008). 
This regime is highly effective against drug-resistant strains of Mtb 
(Kurz and Bonomo, 2012; Ramón-Garciá et al., 2016). Unfortunately, 
research has suggested that there are point mutations in BlaC that could 
enable this β-lactamase to hydrolyse the clavulanic acid (Soroka et al., 
2015). 
D-cycloserine is a second-line drug, active against drug resistant 
mycobacteria (MDR and XDR) (World Health Organisation, 2018), that 
targets the biosynthesis of PG. As an analogue of D-Ala, it is a compe-
titive inhibitor for both alanine racemase (Alr), the enzyme that con-
verts alanine between the L- and D- forms (Halouska et al., 2007), and 
Ddl, which forms the terminal D-Ala:D-Ala dipeptide of the PG’s peptide 
sidechains (Bruning et al., 2011; Halouska et al., 2014). While both 
enzymes are inhibited by D-cycloserine, Alr inhibition is not lethal 
(Halouska et al., 2007) and the bacteriostatic effect in mycobacteria is 
caused by the inhibition of Ddl (Halouska et al., 2014; Prosser and de 
Carvalho, 2013); though Alr inhibition may indirectly enhance D-cy-
closerine potency by decreasing the available D-Ala to compete for Ddl 
(Halouska et al., 2014). D-cycloserine is an attractive drug, with ex-
tremely low levels of spontaneous resistance in clinical strains, which 
could be explained by the observed in vivo fitness costs of the few re-
sistance mutations that have arisen in Mtb (Evangelopoulos et al., 
2019). Most known resistance mechanisms occur in Alr, including a 
point mutation (aspartic acid-322 to asparagine) (Coll et al., 2018), and 
a promotor mutation that leads to Alr overexpression; this latter mutant 
has increased levels of D-Ala, which outcompete the D-cycloserine for 
Ddl binding (Halouska et al., 2014; 2007; Nakatani et al., 2017). 
Vancomyin, a glycopeptide that binds to the terminal D-Ala:D-Ala 
and prevents cross-linking of the pentapeptide side chains (Reynolds, 
1989), is mainly used to treat Gram-positive bacteria due to its inability 
to cross the outer membrane of Gram-negatives and mycobacteria. 
However, vancomycin could prove useful in mycobacteria if used in 
combination with inhibitors of cell wall synthesis enzymes, such as 
ethambutol (Arain et al., 1994; Soetaert et al., 2015). Ramoplanin (Wu 
et al., 2015), enduracidin and teixobactin (Ling et al., 2015; Piddock, 
2015) are inhibitors that bind directly to Lipid II, preventing transgly-
cosylation of the glycan backbone. Ramoplanin and enduracidin are 
structurally related, though an additional mannose moiety on ramo-
planin enhances solubility (Wu et al., 2015). Teixobactin is a peptide- 
like antibiotic, derived from uncultured soil bacteria, that is active 
against Gram-positive bacteria and Mtb, with low levels of spontaneous 
resistance (Ling et al., 2015; Piddock, 2015). 
The bi-functional enzyme, GlmU, which is involved in UDP-GlcNAc 
synthesis, is essential (Zhang et al., 2008), and several inhibitors have 
been examined, including substrate analogues (Li et al., 2011) and the 
natural compounds dicumarol and coumarin (Han et al., 2019). There 
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are a number of naturally occurring nucleoside antibiotics, including 
capuramycin, caprazamycin, liposidomycin and muraymycin, that 
target MurX, the essential translocase that produces Lipid I (Boyle and 
Donachie, 1998; Dini, 2005). Several derivatives of capuramycin have 
been made, some of which are active against non-replicating Mtb 
(Reddy et al., 2008; Siricilla et al., 2015). The most successful deriva-
tive is SQ641, which has been through pre-clinical trials, though its 
poor aqueous solubility is disadvantageous (Pstragowski et al., 2017; 
Reddy et al., 2008). 
2.4. Arabinogalactan structure 
Arabinogalactan (AG) is a tree-like structure composed of a ga-
lactose trunk with arabinose branches, covalently attached to the PG via 
a rhamnose-GlcNAc linker unit at the base of the trunk (Fig. 3A) 
(Lechievalier and Lechievalier, 1970; McNeil et al., 1987). The main 
trunk structure consists of approximately 30 β-D-galactofuranose re-
sidues (Galf) with alternating β(1 → 5) and β(1 → 6) linkages (Daffé 
et al., 1990). This is elaborated with three arabinofuranose (Araf) 
branches, all of which are attached to the 6-linked Galf residues at the 
8th, 10th, and 12th positions of the trunk (Alderwick et al., 2005; Besra 
et al., 1995; Daffé et al., 1990). The initial Araf residues are connected 
via α(1 → 5) linkage and are further extended with α(1 → 5) linked 
Araf (Daffé et al., 1990) residues. The arabinan is a highly branched 
structure and these branch points are introduced with α(1 → 3) linked 
Araf residues (Daffé et al., 1990). The chains terminate at the non-re-
ducing ends with a characteristic branched hexa-arabinoside unit 
(Araf6), comprising [β-D-Araf-(1 → 2)-α-D-Araf]2–3,5-α-D-Araf-(1 → 
5)-α-D-Araf (Daffé et al., 1990). The terminal and penultimate Araf 
residues of the Araf6 unit provide the anchoring points for the cell wall 
bound mycolic acids, of which two thirds are mycolated (Mcneil et al., 
1991). Interestingly, some of the 3,5-branch point Araf residues have 
been found to be modified on the position 2 with either a galactosamine 
or a succinyl residue (Bhamidi et al., 2008; Draper et al., 1997; Lee 
et al., 2006; Peng et al., 2012; Škovierová et al., 2010). The purpose of 
these alterations is not certain, though the additional galactosamine has 
been found to confer protection from the host’s immune system 
(Škovierová et al., 2010). Also it is speculated that the galactosamine 
and succinyl residues could interact to increase the stability of the 
arabinan domain; the protonated galactosamine has a positive charge 
and could interact with either the phosphate groups of the membrane 
lipids or with the negatively charged succinyl residues (Bhamidi et al., 
2008). 
2.5. Arabinogalactan biosynthesis 
AG biosynthesis (Fig. 3B) begins in the cytoplasm with the synthesis 
of the rhamnose-GlcNAc linker unit, α-L-rhamnopyranoside-(1 → 3)-α- 
D-GlcNAc(1 → P), that connects the AG with the PG. WecA (Rv1302), a 
GlcNAc-1-P transferase, first produces C50-P-P-GlcNAc, using C50-P and 
GlcNAc-1-P (Jin et al., 2010), to which L-rhamnose is added from 
dTDP-rhamnose, by WbbL (Rv3265c), a rhamnosyltransferase (McNeil 
et al., 1990; Mills et al., 2004). The decaprenyl-phosphate anchors the 
resulting rhamnose-GlcNAc linker unit to the inner membrane, with the 
sugar groups pointing into the cytoplasm. The galactan chain is con-
structed here using the soluble substrate, UDP-Galf. The dual activity of 
the galactofuranose transferase, GlfT1 (Rv3782), sequentially poly-
merises the addition of two priming Galf residues onto the rhamnose of 
the linker unit (Alderwick et al., 2008; Mikušová et al., 2006): the first 
Galf is transferred via β(1 → 4) linkage to the D-rhamnose, and the 
second Galf has β(1 → 5) linkage to the first Galf residue (Belánová 
et al., 2008). GlfT2 (Rv3808c) then polymerises approximately 28 Galf 
residues with alternating β(1 → 6) and β(1 → 5) linkages (Kremer et al., 
2001a; Rose et al., 2006). At this point, the galactan domain, C50-P-P-N- 
acetylglucosamine-L-rhamnose-galactofuranose30, is transported across 
the inner membrane to the periplasm. There are two candidates for this 
role, Rv3781 and Rv3783, both of which encode ABC transporters 
(Dianišková et al., 2011). 
The arabinan domain is assembled onto the galactan by membrane- 
bound arabinofuranosyl transferases (AraT) in the periplasm, using the 
lipid donor substrate decaprenylphosphoryl-β-D-arabinofuranose 
(DPA) (Wolucka et al., 1994). The DPA is synthesised in the cytoplasm 
from ribose-5-phosphate: PrsA (Rv1017c), a ribose-phosphate pyr-
ophosphokinase, first adds a pyrophosphate group from ATP to position 
C1 of the ribose, to generate 5-phosphoribose-1-diphosphate (pRpp) 
(Alderwick et al., 2011b). UbiA (Rv3806c) (a decaprenyl-phosphate 
phosphoribosyltransferase) substitutes the terminal phosphate group 
from the pyrophosphate for a decaprenyl phosphate (C50-P), anchoring 
it to the inner membrane as decaprenylphosphoryl-β-D-5-phosphor-
ibose (DPPR) (Alderwick et al., 2005; Huang et al., 2008; 2005), and 
Rv3807c (a putative phospholipid phosphatase) dephosphorylates po-
sition C-5 (Jiang et al., 2011). The resulting decaprenylphosphoryl-β-D- 
ribose (DPR) undergoes an epimerization reaction of the ribose, cata-
lysed by the decaprenylphosphoribose-2′-epimerase, DprE1 (Rv3790) 
and DprE2 (Rv3791), to produce DPA (Mikušová et al., 2005). The DPA 
is then flipped across the inner membrane, reorienting the Araf residue 
into the periplasm. Rv3789 was initially thought to be the DPA trans-
porter (Larrouy-Maumus et al., 2012), though a role in AftA recruit-
ment has also been suggested (Kolly et al., 2015). 
In the periplasm, the C50-P-P-GlcNAc-L-rhamnose-galactofuranose30 
(galactan domain) is primed by the AraT, AftA (Rv3792), with three 
α(1 → 5) linked Araf residues on the C-5 of the β(1 → 6) Galf residues 
at positions 8, 10, and 12 (Alderwick et al., 2006; 2005). The main body 
of the arabinan is then constructed by a combination of different AraTs, 
which introduce straight chains and branch points. Initially, the EmbA 
(Rv3794)/EmbB (Rv3795) heterodimer was thought to polymerise the 
longer chains of α(1 → 5) arabinose chains (Alderwick et al., 2005; 
Khasnobis et al., 2006; Zhang et al., 2020). The role of EmbAB is evi-
denced by a knock-out of the sole emb gene in the related bacteria, C. 
glutamicum, which abolished all AG synthesis, apart from the initial 
priming Araf (Alderwick et al., 2005). A knock-out of both proteins is 
lethal in M. smegmatis, but a single deletion of either embA or embB, 
only demonstrated a role in the construction of the terminal hexa-ara-
binoside unit, which lacked the terminal branch point in the mutants 
(Escuyer et al., 2001; Khasnobis et al., 2006; Lee et al., 1997). For-
mation of the terminal branch points, with α(1 → 3) linkage, has since 
been confirmed with the purified EmbAB enzyme complex (Zhang 
et al., 2020). It could be that the EmbAB dimer possesses both α(1 → 5) 
elongation and α(1 → 3) branch point activity, but that the α(1 → 5) 
activity is redundant in the embA or embB knock-outs, compensated for 
by the remaining EmbB or EmbA protein, respectively. Certainly, there 
is not currently an alternative candidate for the α(1 → 5) elongation. 
Earlier branch points in the AG are introduced by AftC (Rv2673) and 
possibly also by AftD (Rv0236c), which incorporate α(1 → 3) linked 
Araf residues (Birch et al., 2008; Škovierová et al., 2009). Addition of 
these branches, followed by extensions, leads to a highly branched 
structure (Alderwick et al., 2005). After the terminal 3,5-branch is 
formed by EmbAB’s α(1 → 3) transferase activity, AftB (Rv3805c) adds 
the terminal Araf residues with a β(1 → 2) linkage (Seidel et al., 2007), 
terminating synthesis with the classic hexa-arabinofuranose cap (Seidel 
et al., 2007). Further modification of the arabinan domain can occur by 
the addition of a D-galactosamine by Rv3779, or succinyl residue by an 
unknown transferase, to the C-2 of the terminal 3,5-branched Araf re-
sidue (Bhamidi et al., 2008; Draper et al., 1997; Lee et al., 2006; Peng 
et al., 2012; Škovierová et al., 2010). The completed AG is ligated to PG 
by the phosphotransferase, Lcp1 (Rv3267) (Harrison et al., 2016). 
2.6. Drugs targeting arabinogalactan and resistance mechanisms 
Ethambutol is a bacteriostatic agent that acts by inhibiting its 
namesake, the Emb proteins (Belanger et al., 1996), preventing the 
polymerisation of arabinan, both in AG synthesis by EmbB (Safi et al., 
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2010; 2008; Starks et al., 2009) and lipoarabinomannan synthesis by 
EmbC (Goude et al., 2009). Ethambutol inhibition in M. smegmatis re-
sults in severely truncated arabinogalactan (Deng et al., 1995; 
Takayama and Kilburn, 1989). In C. glutamicum, only the galactan 
backbone and the priming arabinose residues remain; these are added 
by AftA, an arabinosyltransferase not affected by ethambutol 
(Alderwick et al., 2006). Ethambutol treatment also prevented the 
mycolic acid layer from covalently linking to the cell wall in M. smeg-
matis, due to the absence of attachment sites on the AG (Takayama and 
Kilburn, 1989). Recent structural studies have described ethambutol 
bound to the active sites of EmbB and EmbC, inhibiting activity by 
competing with the arabinose of both the donor and acceptor substrates 
(PDB IDs: 7BVC, 7BWR, 7BVG, 7BVF, 7BVE and 7BVH) (Zhang et al., 
2020). Interestingly, all three Emb proteins co-purified with the FAS-II 
acyl carrier protein, AcpM, bound to their cytoplasmic exposed surface, 
though more work is required to determine the function of this protein 
in AG/LAM assembly (Zhang et al., 2020). Resistance to ethambutol 
predominantly occurs with mutations in EmbB (93.7%), most of which 
are substitutions of methionine-306 to a branched chain amino acid 
(isoleucine, leucine or valine) (Zhao et al., 2015). 72.7% of all MDR 
strains identified have mutations in EmbB, which reflects the universal 
application of ethambutol as a front-line drug (Zhao et al., 2015). 
The nitrobenzamine drug, BTZ, has uncovered DprE1 as another 
useful target in the AG pathway; this drug is active in low doses against 
both MDR and XDR strains (Makarov et al., 2009; Pasca et al., 2010). 
DprE1 acts as an epimerase along with DprE2, converting DPR to DPA, 
the substrate used by all arabinosyltransferases in Mtb (Wolucka et al., 
1994). Inhibition occurs when the nitro group of BTZ is converted by 
DprE1 to a nitroso group, which then forms a covalent bond with the 
active site cysteine-387 (Batt et al., 2012; Makarov et al., 2009; Neres 
et al., 2012; Trefzer et al., 2010). Though resistance can develop 
through the substitution of this cysteine for a serine (Makarov et al., 
2009), there are several inhibitors in the pipe-line, including TCA1 
(Wang et al., 2013), GSK710 (Batt et al., 2016) and Azaindole (Chatterji 
et al., 2014), that do not rely on cysteine-387 for inhibition. 
The caprazamycin derivative, CPZEN-45, inhibits WecA (Ishizaki 
et al., 2013), an essential protein involved in the synthesis of the unique 
rhamnose-GlcNAc linker between AG and PG (Huszár et al., 2017; Jin 
et al., 2010). While CPZEN-45 has good pharmacological properties and 
is active against MDR strains, it has poor bioavailability and so is cur-
rently being trialled for inhalation therapy in combination with the 
unrelated second-line drug, capreomycin (Pitner et al., 2019). The 
substrate UDP-Galf is not utilised in humans (Peltier et al., 2008; Tefsen 
et al., 2012) and so substrate analogues could be exploited to target the 
galactofuranosyltransferases, GlfT1 and GlfT2, although none to date 
have sufficient activity against the enzyme or whole cell (Konyariková 
et al., 2020). 
2.7. Structures of the mycolic acids 
Mycolic acids (MA), an abundant lipid of Mtb, are covalently at-
tached to two-thirds of the non-reducing ends of the AG, where they 
extend out, perpendicular to the inner membrane, forming the inner 
leaflet of the MOM (Mcneil et al., 1991; Minnikin, 1982). Since they are 
long chains of 70–90 carbons (α-alkyl-β-hydroxy fatty acids), the MAs 
fold into energetically favourable conformations, which is dependent 
on their structural features. This enables tight packing within the layer, 
forming an impermeable hydrophobic barrier, which is essential for 
viability (Bhatt et al., 2005; Brown et al., 2007) and pathogenesis 
(Dubnau et al., 2000; Glickman et al., 2000; Peyron et al., 2008; Rao 
et al., 2006; Yuan et al., 1998), while also preventing antibiotic entry 
into the cell (Jarlier and Nikaido, 1994; Liu and Nikaido, 1999). While 
Fig. 4. Chemical features of mycolic acids and biosynthesis A) Structures and common conformations of the three classes of MAs: i) α-, ii) Methoxy- and iii) Keto- 
(Minnikin et al., 2015). B) Mycolic acid biosynthesis. 
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some MAs are linked to the cell wall, others are present as extractable 
lipids in the outer leaflet of the MOM. The majority of the extractable 
MAs are linked to trehalose as trehalose monomycolates (TMM) and 
trehalose dimycolates (TDM), though free mycolates are also present, 
particularly in latent phase cells (Bacon et al., 2014). TMM and TDM 
are thought to be intermediates in the formation of the MA layer 
(Kremer and Besra, 2005), though TDM, the ‘cord factor’, also has roles 
in pathogenicity. TDM interacts with the macrophage receptor Mincle, 
a C-type lectin receptor, preventing acidification of the phagosome and 
enabling granuloma formation (Hunter et al., 2006; Indrigo et al., 2003; 
Ishikawa et al., 2009; Patin et al., 2017). The free mycolates have also 
been found to promote granuloma formation, which correlates with 
their abundance in latent cells (Bacon et al., 2014). 
MAs are formed of two parts that can be cleaved at high tempera-
tures: the meromycolate moiety is a long chain meroaldehyde of up to 
62 carbons, usually with two functional groups, including cyclopropane 
rings, methyl groups and oxygen functions (Asselineau and Lederer, 
1950; Barry et al., 1998). The α-branch is a shorter, saturated chain of 
24–26 carbons, without functional groups (Asselineau and Lederer, 
1950). The three classes of MAs in Mtb (Fig. 4A) consist of α-mycolates, 
methoxymycolates and ketomycolates. The α-MAs are the most abun-
dant and contain only cis-cyclopropane rings, while the oxygenated 
methoxy-MAs and keto-MAs have either a cis-cyclopropane ring, or a 
trans-cyclopropane ring with an adjacent methyl branch (Brennan and 
Nikaido, 1995; Minnikin, 1982). Methoxy-MAs are more abundant with 
cis-cyclopropane rings, while keto-MAs are more common with trans- 
cyclopropane rings (Watanabe et al., 2002). The cyclopropane rings 
introduce kinks into the long chains (Brennan and Nikaido, 1995), 
which along with hydrophilic interactions from the oxygen functions 
(Villeneuve et al., 2005), enables the MAs to fold into different con-
formational shapes. The keto-MAs typically adopt a ‘W’ shape, packing 
together four chains in parallel (Villeneuve et al., 2007; 2005), while 
the α- and methoxy-MAs are more flexible and can take on more open 
structures (Groenewald et al., 2014). Interestingly, the ‘W’ conforma-
tions of the keto-MAs are reliant on the trans-configuration of the cy-
clopropane ring, a feature that could support a more tightly packed MA 
layer in strains with a higher proportion of trans-rings (Villeneuve et al., 
2013) and could explain the requirement of keto-MAs for virulence 
(Sambandan et al., 2013; Yuan et al., 1998). 
2.8. Mycolic acid biosynthesis 
Fatty acid synthase-I (FAS-I) (fas; Rv2524c) is the only system in 
Mtb capable of synthesising fatty acids de novo. Uniquely to myco-
bacteria, the product distribution is bimodal, and the synthesised fatty 
acids can be one of two different chain lengths: either longer, C24-C26 
chains, or shorter chains of C16-C18 (Bloch and Vance, 1977; Peterson 
and Bloch, 1977). In MA synthesis, the C24-C26 chains produce the α- 
branch, while the shorter chains are elongated by FAS-II to form the 
meromycolate moiety. FAS-I is a ‘eukaryotic-like’ multi-domain en-
zyme, a single protein with all the catalytic domains for fatty acid 
synthesis: acyl transferase (AT), enoyl reductase (ER), dehydratase 
(DH), malonyl/palmitoyl transferase (MPT), acyl carrier protein (ACP), 
β-keto reductase (KR) and β-ketoacyl synthase (KS) (Fernandes and 
Kolattukudy, 1996). Synthesis commences with the transfer of an 
acetate from Coenzyme A (CoA) to the ACP domain (Fig. 4B). During 
each cycle the chain is extended by two carbons (acetate) from the 
extender unit, malonyl-CoA, which is produced through the carbox-
ylation of acetyl-CoA by the acyl-CoA carboxylase complex (ACCase) 
(Cronan and Waldrop, 2002). The mechanism employed to produce 
fatty acid products with two quite different chain lengths, is complex 
and could involve interactions between several components of both FAS 
systems. Also implicated in this are endogenous polysaccharides, con-
taining either 3-O-methyl-D-mannose or 6-O-methyl-D-glucose, which 
have been shown to favour the shorter chain lengths by complexing 
with these products and facilitating their release from the FAS-I 
complex (Banis et al., 1977; Papaioannou et al., 2007; Wood et al., 
1977). 
FAS-II is a ‘prokaryote-like’ fatty acid synthase, a complex of dis-
crete enzymes that correspond to the catalytic domains of FAS-I. The 
extender unit, malonyl is presented on an acyl carrier protein (AcpM; 
Rv2244), which is transferred from malonyl-CoA by the transacylase, 
FabD (Rv2243) (Kremer et al., 2001b). FabH (Rv0533c), a β-ketoacyl 
ACP synthase, shuttles the shorter C16-C18 acyl-CoA chains from FAS-I 
to FAS-II, through a Claisen-like condensation with malonyl-AcpM 
(Choi et al., 2000). The resulting β-ketoacyl-AcpM is presented to the 
FAS-II enzymes, where the keto group is reduced by the keto-reductase, 
MabA (Rv1483), to form β-hydroxylacyl-AcpM (Marrakchi et al., 
2002). The dehydratase heterodimers, HadAB (Rv0635-Rv0636) and 
HadBC (Rv0636-Rv0637) convert this to enoyl-AcpM (Brown et al., 
2007; Sacco et al., 2007), which is then reduced to acyl-AcpM by the 
enoyl-CoA reductase, InhA (Rv1484) (Banerjee et al., 1994). Further 
rounds are then initiated by the β-ketoacyl synthases, KasA/B (Rv2245 
and Rv2246), extending the chain by an acetate each cycle (Kremer 
et al., 2002a; Schaeffer et al., 2001). FAS-II extends the acyl chain to 
C18-C32, after which modifications, such as further extensions to C42- 
C62, cis-/trans- cyclopropanations, methylations and methoxy-/keto- 
group additions, produce the mature meromycolate chain (Barkan 
et al., 2010; Glickman, 2003; Glickman et al., 2000; Barry et al., 1998). 
Pks13 (Rv3800c) is an iterative Type I polyketide synthase (PKS) 
that joins together the two branches of the MAs through a Claisen-like 
condensation (Portevin et al., 2004). This involves the action of FadD32 
(Rv3801c), a fatty-acyl-AMP ligase, which activates the meromycolyl- 
AcpM to meromycolyl-AMP and loads the acyl chain onto the N-term-
inal ACP of Pks13 (Léger et al., 2009; Trivedi et al., 2004). The α- 
branch is carboxylated by the ACCase complex, a step that is necessary 
for the Claisen-type reaction (Gande et al., 2007), and loaded onto the 
C-terminal ACP domain of Pks13 (Gavalda et al., 2014). The product of 
the condensation reaction is then transferred onto a trehalose by Pks13, 
producing α-alkyl β-ketoacyl trehalose monomycolate (TMMk) 
(Gavalda et al., 2014) and CmrA (Rv2509) reduces the keto group to 
produce the mature trehalose monomycolate (TMM) (Bhatt et al., 2008; 
Lea-Smith et al., 2007). The TMM is transported across the inner 
membrane by MmpL3 (Rv0206c) (Grzegorzewicz et al., 2012; Tahlan 
et al., 2012). In the periplasm, a complex of secreted proteins with 
mycolyltransferase activity, known as the Antigen 85 complex (Ag85A, 
Ag85B, Ag85C; Rv3804c, Rv1886c, Rv0129c), attach the TMM either 
directly to the AG to form mAG (mycolylarabinogalactan), or to an 
acceptor TMM, producing TDM (Belisle et al., 2009; Jackson et al., 
1999). These processes release trehalose, a significant sugar for Mtb, 
which is recycled back into the cell by LpqY-SugA-SugB-SugC (Rv1235- 
Rv1236-Rv1237-Rv1238), an essential ABC sugar transporter 
(Kalscheuer et al., 2010). 
2.9. Drugs targeting mycolic acid biosynthesis and resistance mechanisms 
MAs are essential for viability and as such the proteins involved in 
MA biosynthesis and transport represent excellent drug targets (Bhatt 
et al., 2005; Brown et al., 2007). The front-line drug, isoniazid (INH), 
and the structurally related second-line drug, ethionamide (ETH), in-
hibit the FAS-II enoyl-CoA reductase, InhA (Banerjee et al., 1994). INH 
is a pro-drug that must first be activated by the peroxidase activity of 
KatG (Rv1908c) (Zhang et al., 1992), forming an INH-NAD adduct that 
competitively inhibits InhA and stalls MA synthesis (Rawat et al., 
2003). Isoniazid has been used to treat tuberculosis since 1952 (Murray 
et al., 2015) and as such resistance has developed with up to 82% of all 
MDR isolates having mutations in the katG gene (Torres et al., 2015), 
which prevents activation of the pro-drug; other resistance mechanisms 
include mutations in the NADH binding pocket of InhA (Banerjee et al., 
1994; Dessen et al., 1995; Rozwarski et al., 1998), which have the 
additional downside of ETH cross-resistance. ETH is also a pro-drug, 
though is activated by an alternative mechanism, EthA (Rv3854c), a 
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monooxygenase that oxidises ETH to the active species (Baulard et al., 
2000; DeBarber et al., 2000; Vannelli et al., 2002); mutations in EthA 
have been identified in up to 76% of ETH-resistant isolates (Morlock 
et al., 2003). The search for further InhA inhibitors, through compound 
library screening for activity against InhA, has revealed a new set of 
thiadiazole inhibitors, the most promising of which is GSK693; this does 
not require activation by KatG and so bypasses this route of resistance, 
and is active against MDR and XDR isolates (Martínez-Hoyos et al., 
2016). The in vitro resistance mutation rate of GSK693 is also much 
lower than that of INH and it is hoped that this will represent a lower 
frequency of spontaneous resistant mutants in clinical isolates; any re-
sistance mutations map to the active site of the inhA gene (glycine-96 or 
methionine-103) (Martínez-Hoyos et al., 2016). 
The β-ketoacyl synthases, KasA/B, are another useful drug target in 
the mycolic acid pathway, with inhibitors including thiolactomycin 
(Kremer et al., 2000), although activity against the whole cell is poor 
(Miyakawa et al., 1982); cerulenin (Schaeffer et al., 2001); and pla-
tensimycin (Brown et al., 2009). Additionally, an indazole sulfonamide, 
GSK724, which targets just KasA, has been found through whole cell 
screening and generation of spontaneous resistant mutants in M. bovis 
BCG (Abrahams et al., 2016). Interestingly, the co-crystal structure of 
KasA with GSK724 has demonstrated that the inhibitor binds to the acyl 
channel, which contrasts to the binding observed for other inhibitors of 
KasA (PDB ID: 5LD8) (Abrahams et al., 2016). Isoxyl and thiacetazone, 
thiocarbamide-containing drugs previously used in the treatment of 
tuberculosis, are pro-drugs that are activated by EthA, and ultimately 
inhibit the FAS-II dehydratase, HadAB (Grzegorzewicz et al., 2015). 
Although discontinued due to their toxic side effects, they nonetheless 
have validated HadAB to be another useful drug target. 
FadD32, which is involved in the condensation of the two MA 
branches, is essential in Mtb (Portevin et al., 2005). Diarylcoumarins 
were initially identified as effective inhibitors that are also active in Mtb 
whole cell and animal models (Stanley et al., 2013), and more chemi-
cally stable derivatives have been synthesised with the addition of a 
quinoline ring (Fang et al., 2018). High-throughput screening (HTS) 
using an assay with purified FadD32 located a further five classes of 
inhibitor: thiopyrimidine, benzimidazole, pyrrozole, quinolone and iso- 
quinolone (Galandrin et al., 2013). 
PKS13, the polyketide synthase that condenses the two branches of 
the MA, is also an essential target (Portevin et al., 2004; Wilson et al., 
2013), with inhibitors including benzofuran, thiophenes and coume-
stan. The benzofuran, TAM16, which is active against MDR and XDR 
strains, inhibits PKS13 by binding to the active site of the thioesterase 
(TE) domain (Aggarwal et al., 2017). Coumestan analogues are derived 
from modifications of benzofuran and similarly inhibit the TE domain 
(Zhang et al., 2018). Thiophenes have a different mechanism to ben-
zofurans, binding to the N-terminal ACP domain and preventing in-
teractions with FadD32 (Wilson et al., 2013). 
The generation of spontaneous resistant mutants to many of the 
recently available drugs found to target Mtb, has identified MmpL3 as a 
potentially significant new drug target (Grzegorzewicz et al., 2012; 
Tahlan et al., 2012). The MmpL proteins are RND (resistance, nodula-
tion and cell division) superfamily membrane proteins (Saier et al., 
1994), involved in lipid transport across the inner membrane. MmpL3 
transports the MA precursor, TMM, and is the only essential MmpL 
protein in Mtb (Domenech et al., 2005). The structural diversity of these 
new drugs, along with their broad-spectrum of targets in other bacterial 
and fungal species, has caused some ambiguity as to their true target in 
Mtb, though many have been demonstrated to bind directly to MmpL3 
in the crystal structure, including SQ109 (1,2-ethylenediamine), 
AU1235 (adamantyl urea) and ICA (indolcarboxamide) (PDB IDs: 
6AJH, 6AJJ, 6AJI, 6AJF and 6AJG) (Zhang et al., 2019). In this study, 
the compounds that were either co-crystallised or modelled to the 
MmpL3 structure, bound to the same part of the central channel in-
volved in proton relay, disrupting critical interactions between aspartic 
acid and tyrosine residues (Zhang et al., 2019). The most promising 
MmpL3 inhibitor is SQ109, which is currently in phase II clinical trials 
in the USA (World Health Organisation, 2019). 
The secreted complex, AG-85, responsible for mycolic acid attach-
ment and TDM synthesis, consists of three related proteins, though 
there is some redundancy (Belisle et al., 1997; Jackson et al., 1999): the 
loss of Ag85B is tolerated, though Ag85A is required for growth in 
macrophages (Armitige et al., 2000) and a deficiency in Ag85C reduces 
mycolic acid transfer to the mAGP complex by 40% (Jackson et al., 
1999). I3-AG85 (2-amino-6-propyl-4,5,6,7-tetrahydro-1-benzothio-
phene-3-carbonitrile) is a derivative of a compound from a library 
found to inhibit Ag85C, which is active against MDR and XDR strains, 
though the MIC is poor (Warrier et al., 2012). Potent analogues of I3- 
AG85 derivatives have been produced using fragment-based drug dis-
covery (Scheich et al., 2010). Cyclipostins/cyclophostins are a new 
class of monocyclic-enolphosphonate that bind covalently to the cata-
lytic serine residue of Ag85C and are potent against Mtb (Viljoen et al., 
2018). Ebselen similarly binds covalently to an active site cysteine in 
Ag85C and is active against MDR strains (Favrot et al., 2014). 
Mycolic acid attachment to AG is also inhibited by the second-line 
drugs, pretomanid and delamanid, though the exact targets are still not 
known (Matsumoto et al., 2006; Stover et al., 2000). Resistant mutants 
have thus far only been generated in ddn, encoding a deazaflavin de-
pendent reductase, and enzymes involved in the synthesis and reduc-
tion of the F420 cofactor (Choi et al., 2001; Manjunatha et al., 2006), 
which is thought to be a drug activation system rather than the target 
(Haver et al., 2015; Hoffmann et al., 2016; Manjunatha et al., 2006). 
2.10. Phosphatidyl-myo-inositol mannosides (PIMs), lipomannan (LM) and 
lipoarabinomannan (LAM) 
Another distinctive feature of the mycobacterial cell wall is the 
presence of three species of glycolipids: phosphatidyl-myo-inositol 
mannosides (PIMs), lipomannan (LM) and lipoarabinomannan (LAM), 
which have been found in abundance, non-covalently bound to the 
inner membrane, and possibly also the outer membrane (Ortalo-Magné 
et al., 1996; Pitarque et al., 2008). The core structure consists of an 
acylated sn-glycero-3-phospho-(1-D-myo-inositol) (PI) unit, glycosy-
lated with up to six α-D-mannopyranosyl (Manp) residues in PIMs and a 
longer Manp core in LM/LAM (Kaur et al., 2007; Mishra et al., 2007), 
with an additional highly branched arabinan domain in LAM (Fig. 5). In 
eukaryotes, various derivatives of the PI unit exist, which are often 
involved in cell signalling (Falasca and Maffucci, 2006; Kutateladze, 
2006; Lindmo and Stenmark, 2006). The mycobacterial PI unit differs 
in that it is glycosylated with Manp residues at the O-2 and O-6 posi-
tions of the inositol ring, forming a mannosyl phosphate inositol (MPI) 
anchor. PIMs exist in varying degrees of mannosylation, carrying 1 to 6 
Manp residues, though tri- and tetra-acylated phospho-myo-inositol 
dimannosides (Ac1PIM2 and Ac2PIM2) and hexamannosides (Ac1PIM6 
and Ac2PIM6) are the most prevalent forms of PIMs in M. bovis BCG, M. 
tuberculosis H37Rv and M. smegmatis (Khoo et al., 1995a). Both forms 
have been shown to be an important structural feature of the inner 
membrane, increasing stability and decreasing permeability to drugs 
(Bansal-Mutalik and Nikaido, 2014). In contrast to the most abundant 
PIMs, LM and LAM are highly mannosylated, commonly carrying a 
chain of 21–34 α(1 → 6) linked Manp residues, interspersed with 5–10 
single branched α(1 → 2) linked Manp units (Chatterjee et al., 1992a). 
LAM has an additional highly branched arabinan layer of 50–80 ara-
binofuranose (Araf) residues, similar to the domain on AG (Khoo et al., 
1996). 
LAM and LM both play an important role in the modulation of the 
host’s immune defences (Schlesinger et al., 1994; Shukla et al., 2018). A 
variety of LAM caps exist, each affecting the immune response in dif-
ferent ways. Mannose capped LAM (ManLAM) is a major Mtb virulence 
factor, which is thought to contribute to the inhibition of the host’s 
immune response, and also to act as the ligand for phagocytosis of Mtb 
(Schlesinger et al., 1994). Conversely, Mtb has been shown to stimulate 
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an immune response through toll-like receptor 2 (TLR2), signalling via 
phosphoinositol-capped LAM (PILAM) and LM, which both act as TLR2 
agonists (Shukla et al., 2018). For these interactions to occur, LM and 
LAM would need to be surface exposed, and indeed it has been shown 
these lipoglycans insert into the outer membrane lipids, in addition to 
those of the inner membrane (Ortalo-Magne et al., 1996; Pitarque et al., 
2008; Sani et al., 2010). However, the issue of LM/LAM location is still 
disputed, with other studies only demonstrating surface exposure in the 
presence of the cell wall inhibitors, isoniazid and ethambutol (Alsteens 
et al., 2008). Also, an outer membrane location would require an as yet 
undiscovered transport system, though a system similar to that of E. coli 
LPS transport has been suggested (Pitarque et al., 2008). Indeed, most 
immunomodulatory studies have relied upon purified components, 
which does not account for surface exposure (Fratti et al., 2003; 
Knutson et al., 1998; Nigou et al., 2001; Vergne et al., 2003), though an 
interaction between ManLAM and the host’s immune system has been 
confirmed using live Mtb (Decout et al., 2018). 
2.11. Biosynthesis of phosphatidyl-myo-inositol mannosides, lipomannan 
and lipoarabinomannan 
The synthesis of these lipoglycans progresses from PIM → LM → 
LAM (Besra et al., 1997) (Fig. 5) and begins in the cytoplasm with the 
production of sn-glycero-3-phospho-(1-D-myo-inositol), a phosphatidy-
linositol (PI) anchored to the inner membrane by two fatty acid chains 
linked to the glycerol moiety. This occurs by way of a two-part process: 
PgsA1 (Rv2612c), a phosphatidylinositol phosphate synthase, initiates 
the biosynthesis of PI by catalysing the conjugation of D-myo-inositol-3- 
phosphate with cytidine diphosphate diacylglycerol (Jackson et al., 
2000; Morii et al., 2010). The phosphatidylinositol phosphate formed in 
this reaction is then broken down into phosphatidylinositol and phos-
phate by an unknown phosphatase (Grāve et al., 2019; Jackson et al., 
2000; Morii et al., 2010). 
A group of GDP-mannopyranose (Manp) dependent cytoplasmic α- 
mannopyranosyltransferases (ManpT), from the GT-A/B (glycosyl-
transferase A/B) superfamily (Liu and Mushegian, 2003; Morita et al., 
2005), are involved in the early stages of PIM biosynthesis, building 
upon the myo-inositol ring of the PI, which is anchored on the cyto-
plasmic face of the inner membrane: PimA (Rv2610c) transfers the first 
Manp to the O-2 position with α(1 → 2) linkage, forming PIM1 (Boldrin 
et al., 2014; Guerin et al., 2007; Korduláková et al., 2002a) and PimB 
(Rv2188c) transfers a second Manp residue with α(1 → 6) linkage to 
position O-6 to form PIM2 (Guerin et al., 2009). An acyltransferase, 
Rv2611c, acylates position C-6 of the Manp residue at position 2 
(Korduláková et al., 2003). It is not entirely clear whether this acylation 
occurs before or after the mannosylation of PIM1, though studies have 
shown that Ac1PIM1 is preferentially formed over Ac1PIM2, suggesting 
that PIM1 is the likely acceptor (Korduláková et al., 2003). An unknown 
transferase acylates the C-3 position of the myo-inositol ring, to form 
the tetra-acylated mannosylated PI anchor (MPI anchor), though the tri- 
acylated form is more abundant (Khoo et al., 1995a). The third and 
fourth Manp residues are added with α(1 → 6) linkage, to the Manp at 
position 6 of the inositol ring, forming Ac1/2PIM3 and Ac1/2PIM4 re-
spectively. The ManpT(s) responsible for this has yet to be determined; 
PimC has been proposed to transfer the first or both of these residues, 
though there appears to be multiple pathways, and while PimC is 
present in M. tuberculosis CDC1551, other mycobacterial species such as 
Mtb H37Rv and M. smegmatis do not carry a homologous gene (Kremer 
et al., 2002b). 
At some point in the synthesis between Ac1/2PIM2-Ac1/2PIM4, the 
mannosylated inositol moiety is transferred across the membrane and 
into the periplasm, possibly by the ABC transporter, Rv1747, though 
there is some redundancy in the pathway (Glass et al., 2017). Here, the 
synthesis of the higher PIMs, LM and LAM is carried out by membrane- 
bound GT-C superfamily ManpTs (Liu and Mushegian, 2003; Morita 
et al., 2005) using polyprenyl-phosphate-based mannose donors, which 
are synthesised by Ppm1 (Rv2051c) (Berg et al., 2007; Gurcha et al., 
2002). Ac1/2PIM4 forms the branch point between the Ac1/2PIM6 
pathway and LM/LAM synthesis. This is mediated by the lipoprotein, 
LpqW (Rv1166) (Kovacevic et al., 2006), knock-outs of which have 
shown that LpqW favours the synthesis of LM/LAM by enhancing the 
activity of the subsequent mannosyltransferase in their synthesis, MptB 
Fig. 5. Biosynthesis of phosphatidyl-inositol-mannosides (PIMs), lipomannan (LM) and lipoarabinomannan (LAM).  
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(Crellin et al., 2008; Rainczuk et al., 2012). PimE (Rv1159) facilitates 
the PIM6 pathway, adding the α(1 → 2) linked fifth and possibly sixth 
mannose residues to the chain of three Manp residues at position 6 of 
the inositol ring, forming Ac1/2PIM5, followed by Ac1/2PIM6 (Morita 
et al., 2006). 
The linear mannose core of LM is also elongated from the chain of 
Manp residues present at position 6 of the inositol ring. MptA (Rv2174) 
and MptB (Rv1459c) add further α(1 → 6) linked Manp residues here 
and knockouts have demonstrated that MptB adds the initial part of the 
chain, followed by MptA (Mishra et al., 2008; 2007). The mature LM 
possesses additional mannose residues arranged as α(1 → 2) linked 
monomannose side chains, which are transferred by MptC (Rv2181) 
(Kaur et al., 2008; Mishra et al., 2011). 
LAM synthesis builds upon a mature LM core, adding a highly 
branched arabinan domain, which is synthesised by membrane-bound 
arabinofuranosyltransferases (AraTs), using DPA (decaprenylpho-
sphoryl-β-D-arabinofuranose) as the arabinose donor (Wolucka et al., 
1994). The mannose core is first primed with Araf (arabinofuranose), 
by an unknown AraT, in what is thought to be a similar process to the 
synthesis of the arabinogalactan domain. The position of this priming is 
not clear and both the O-2 (Chatterjee et al., 1993) and O-6 (Angala 
et al., 2016) positions on the mannose have been implicated, the latter 
of which would prevent attachment of the arabinan domain to all but 
the last mannose residue in the core. EmbC (Rv3793) then elongates the 
primed core, adding 12–16 α(1 → 5) linked Araf residues (Alderwick 
et al., 2011a; Shi et al., 2006). Branching is introduced into the linear 
arabinan chain by AftC (Rv2673), which adds α(1 → 3) linked Araf 
residues (Birch et al., 2008). It has been postulated that AftD (Rv0236c) 
initiates further α(1 → 3) branching, although this is unconfirmed 
(Škovierová et al., 2009). AftB (Rv3805c) terminates the arabinan with 
β(1 → 2) linked Araf (Jankute et al., 2017). The structure of the ara-
binan domain, by this point is highly branched, though the non-redu-
cing ends are less branched than those of AG, with a linear tetra-ara-
binoside motif more common than the branched hexa-arabinoside of AG 
(Chatterjee et al., 1993). CapA (Rv1635c), a PPM dependent α(1 → 5) 
ManpT, primes the arabinan termini for capping by adding a single 
Manp residue (Dinadayala et al., 2006). MptC is responsible for further 
mannosylation of the cap through the additions of one to three α(1 → 
2) Manp residues (Kaur et al., 2008). In M. tuberculosis, a substitution 
occurs in approximately 15–20% of mannose caps replacing mannose 
with a single α-(1 → 4) linked methylthio-D-xylose residue (Angala 
et al., 2017; Ludwiczak et al., 2002; Turnbull et al., 2004). The dec-
oration of LAM varies between mycobacterial species: while Mtb and 
other slow-growing pathogenic strains have up to three mannose re-
sidues (Chatterjee et al., 1992b), phospho-inositol (PI) capped LAM 
(PILAM) is more common in non-pathogenic species, such as M. smeg-
matis (Khoo et al., 1995b); some rapid-growing species such as M. 
chelonae lack mannose and PI caps entirely (Guerardel et al., 2002). 
2.12. Drugs targeting the biosynthesis phosphatidyl-myo-inositol 
mannosides, lipomannan and lipoarabinomannan and the mechanisms of 
resistance 
Although strains expressing truncated forms of LAM are viable 
(Goude et al., 2009), no strains completely lacking LAM have been 
grown, indicating a role in viability (Korkegian et al., 2014). This is 
confirmed by the essentiality of the major arabinosyltransferase in-
volved in LAM synthesis, EmbC, in Mtb (Goude et al., 2008). Analo-
gously to EmbB, EmbC is inhibited by the front-line drug ethambutol 
(Goude et al., 2009), and structural studies have demonstrated 
ethambutol binding to the active site of EmbC (PDB ID: 7BVE) (Zhang 
et al., 2020). Although, EmbB is considered the primary target of 
ethambutol, treatment also results in truncated LAM, and over-
expression of EmbC can confer resistance to ethambutol, indicating that 
inhibition of LAM biosynthesis is a part of ethambutol activity (Goude 
et al., 2009). Interestingly, the structure of EmbC has recently 
demonstrated an association with the FAS-II protein AcpM, as also seen 
with EmbAB. While the function of AcpM with these arabinosyl-
transferases is not clear, mutating the amino acid side chains of EmbC 
involved in these contacts, reduced the LAM content, suggesting a role 
in synthesis and activity (Zhang et al., 2020). DprE1 is critical to the 
synthesis of the arabinosyltransferase donor, DPA, and so the inhibitors 
of this enzyme, which were discussed earlier in relation to AG, would 
also prevent synthesis of the arabinan domain of LAM (Makarov et al., 
2009). 
Many of the drugs targeting the LM/LAM pathway have so far been 
substrate analogues, with targets including PimA, PimB and Ppm1 
(Brown et al., 2001; Dinev et al., 2007; Subramaniam et al., 2005), 
known to be essential enzymes in either M. smegmatis or Mtb 
(Korduláková et al., 2002b; Rana et al., 2012; Torrelles et al., 2009). A 
galactose phosphonate analogue of PI was found to inhibit PimA in a 
cell-free, but not a whole-cell assay (Dinev et al., 2007). More recently, 
however, there has not been much progress in the way of new inhibitors 
of this pathway, which could reflect a reduced role of LM/LAM in Mtb 
viability, as compared to the mAGP complex, or a deficiency of research 
into inhibitors of pathogenicity. 
3. Conclusions 
The cell wall of mycobacteria is essential for viability and virulence, 
and the complex pathways responsible for its synthesis contain a ple-
thora of essential enzymes, which could be targets for new antibiotics. 
Currently, although there is a great deal of research into drugs and 
targets for Mtb, most new drugs are initially found through whole cell 
assays, and the targets later located through spontaneous mutant gen-
eration. This process is lengthy and prone to error, with mutations often 
generated in drug activation pathways (Haver et al., 2015; Hoffmann 
et al., 2016; Juréen et al., 2008; Manjunatha et al., 2006; Morlock et al., 
2003; Stoffels et al., 2012; Torres et al., 2015), and efflux pumps (such 
as MmpL5 and MmpL7) (Halloum et al., 2017; Hartkoorn et al., 2014; 
Milano et al., 2009). Indeed, the targets of many drugs, such as pre-
tomanid, delamanid and pyrazinamide, are yet to be found. 
Future research in drug discovery will likely take a more targeted 
approach as our understanding of this complex pathogen improves: new 
targets will be chosen due to their uniqueness and essentiality; target- 
based enzyme assays will be developed on a HTS basis to rapidly screen 
large compound libraries; and structural studies and modelling will be 
used to improve the properties and binding of any identified inhibitors. 
Examples of this shift in research methods have been touched upon 
here. One such instance is the GlaxoSmith Kline (GSK) library screen 
against the validated old target, InhA, revealing a new set of inhibitors, 
the thiadiazoles (Martínez-Hoyos et al., 2016). Additionally, HTS assays 
have also been developed for new targets, such as WbbL 
(Grzegorzewicz et al., 2008), WecA (Mitachi et al., 2016), FadD32 
(Galandrin et al., 2013) and Ag85 (Boucau et al., 2009), so that drug 
libraries can be screened specifically for inhibition of these targets. One 
downside to these in vitro screening methods, that whole cell activity is 
not demonstrated, is particularly significant for Mtb, which has such an 
impenetrable hydrophobic barrier to antibiotics in the form of its un-
ique cell wall; though this could be easily remedied by first screening 
libraries for activity against the whole cell. Another useful targeted 
approach to drug development is whole-cell target overexpression, 
which has been used to find a novel inhibitor of DprE1, GSK710 (Batt 
et al., 2016). This technique overexpresses the target protein in Mtb or 
related bacteria and identifies inhibitors as having an associated in-
crease in the concentration of compound required to inhibit the cell; it 
has the added benefit of demonstrating activity not only against the 
target protein, but the whole cell too. 
Structural research, even of membrane proteins, has exploded in 
recent years; this has been aided by advances in technology, particu-
larly cryo-EM, which now has resolution that rivals X-ray crystal-
lography. Cryo-EM has been used to resolve the structures of the targets 
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of the front-line drug ethambutol, the Emb proteins, demonstrating 
both the inhibitor binding mechanism and Emb co-localisation with the 
FAS-II acyl carrier protein, AcpM (Zhang et al., 2020). Crystal studies 
have also revealed the structure of the exiting new target MmpL3, the 
membrane protein involved in mycolic acid transport and the target of 
many new antibiotics under development (Zhang et al., 2019). The 
MmpL proteins are involved in lipid transport across the inner mem-
brane, an important process in Mtb. While MmpL3 is the only essential 
MmpL protein, others are important for virulence (Domenech et al., 
2005) and should not be discounted as useful targets in the future. 
Despite the increased efforts into drug discovery, only two new 
antibiotics have been approved in the last 40 years, bedaquiline and 
delamanid (Andries et al., 2005; Thakare et al., 2015). Hopefully, as our 
insight into the mechanisms of this powerful pathogen improves, a 
more targeted approach should be more productive in the discovery 
and approval of new antibiotics. 
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